Gylden Pharma Ltd

This is a first-in-human study to check the safety and immune response of a new experimental vaccine against chikungunya virus. The trial will enroll 40 healthy adults aged 18-60 who will receive two injections six weeks apart. Researchers will closely monitor participants for si…